Key clinical point: Rozanolixizumab, a subcutaneous antibody targeting the human neonatal Fc receptor, provides clinically meaningful improvements in platelet count for patients with primary immune thrombocytopenia.
Major finding: Out of 12 patients, 8 in the highest dose group achieved platelet counts of 5 x 109/L or higher.
Study details: A phase 2, open-label study involving 54 patients with immune thrombocytopenia.
Disclosures: The investigators reported financial relationships with Celgene, Roche, GlaxoSmithKline, Amgen, AbbVie, and other companies.
Robak T et al. EHA Congress, Abstract S850.